合并癌症的产妇静脉血栓栓塞症发生率高
该回顾性队列研究利用2015年10月至2020年12月全国再入院数据库,分析合并癌症诊断的产妇产后静脉血栓栓塞症风险。癌症患者42天和330天静脉血栓栓塞症发生率分别为1.11%和2.19%,无癌症者为0.11%和0.14%。330天调整相对风险为9.68(95%CI 7.18-12.18),剖宫产风险更高,结论需进一步研究最佳预防策略。
要点
- 合并癌症的产妇42天静脉血栓栓塞症发生率为1.11%,330天为2.19%。
- 无癌症产妇42天和330天静脉血栓栓塞症发生率分别为0.11%和0.14%。
- 330天调整相对风险为9.68(95%CI 7.18-12.18),剖宫产者风险更高。
核心结论
- 妊娠期癌症带来超出产后即刻阶段的额外血栓栓塞风险。
- 需进一步研究以确定该人群最佳静脉血栓栓塞症预防策略。
研究设计与样本
- 回顾性队列研究,使用2015年10月至2020年12月大型全支付方全国再入院数据库。
- 研究人群包括9 793 503例分娩住院(加权估计18 207 346例),其中加权估计10 428例(0.06%)孕妇合并癌症。
- 主要结局为分娩入院日期后42天和330天静脉血栓栓塞症发生率,比较合并与不合并癌症诊断的患者。
- 次要分析按癌症诊断和分娩途径分层评估静脉血栓栓塞症风险,使用逆概率加权生存曲线比较结局。
主要发现
- 合并癌症者42天和330天静脉血栓栓塞症发生率分别为1.11%和2.19%,无癌症者分别为0.11%和0.14%。
- 330天时,未调整相对风险为15.52(95%CI 11.54-19.51),调整后相对风险为9.68(95%CI 7.18-12.18)。
- 按癌症类型和分娩途径分层显示各癌症类型静脉血栓栓塞症风险均升高,剖宫产 conferring 更大风险。
- 合并癌症者较无癌症者年龄更大,合并症发生率更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究以确定该人群最佳静脉血栓栓塞症预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) risk is increased independently by both cancer and pregnancy. OBJECTIVES: To estimate VTE risk in the postpartum period among patients delivering with a cancer diagnosis, stratified by cancer type and delivery route. METHODS: We performed a retrospective cohort study utilizing the large, all-payer Nationwide Readmissions Database from October 2015 through December 2020. We identified delivery hospitalizations, cancer diagnoses, and VTE using patient demographics and diagnosis codes. The primary outcome was VTE incidence at 42 and 330 days from delivery admission date, comparing patients with and without cancer diagnoses. A secondary analysis included VTE risk stratified by cancer diagnosis and delivery route. Outcomes were compared using inverse probability-weighted survival curves. RESULTS: The study population included 9 793 503 delivery hospitalizations (weighted estimate, 18 207 346), with a weighted estimate of 10 428 (0.06%) pregnant patients with cancer. Individuals with cancer were older, with higher rates of comorbid conditions, than those without cancer. VTE incidence in individuals with cancer at 42 and 330 days was 1.11% and 2.19%, respectively, vs 0.11% and 0.14%, respectively, in those without cancer. At 330 days, this finding was significant in both unadjusted (relative risk, 15.52; 95% CI, 11.54-19.51) and adjusted (relative risk, 9.68; 95% CI, 7.18-12.18) models. Stratification by cancer type and delivery route demonstrated elevated VTE risk across cancer types, with cesarean delivery conferring a greater risk. CONCLUSION: Cancer in pregnancy confers excess thromboembolic risk extending beyond the immediate postpartum period. Further study is needed to identify optimal VTE prophylactic strategies for this population.
引用
- Cate JJM, Sundermann AC, Campbell AIK, et al. High rates of venous thromboembolism among deliveries complicated by cancer. J Thromb Haemost. 2023. PMID: 37353083. doi:10.1016/j.jtha.2023.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。